# Roivant Sciences Ltd. Common Shares (ROIV) — Stock CV

Roivant Sciences Ltd. is a $25.6B healthcare company. Revenue shrank 21.4% over the last year, it currently loses money, and it holds more cash than debt.

> Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

## Identity

- **Ticker**: ROIV
- **Sector**: Healthcare
- **Industry**: Pharmaceutical Preparations
- **Headquarters**: LONDON
- **Employees**: 721
- **Website**: https://www.roivant.com
- **Market cap**: $25.6B
- **Last price**: $35.44
- **Financial profile**: Strong

## Vitals (TTM)

- **Revenue**: $16.9M
- **Net income**: -$1.28B
- **Free cash flow**: -$1.89B
- **Net cash**: $3.73B
- **Revenue growth (YoY)**: -21.4%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 45 |
| Growth | 0 |
| Profitability | 0 |
| Health | 75 |
| Quality | 12 |
| Moat | 0 |

## Qualifications (beginner checklist) — 5 of 9 passed

- [ ] Revenue growing — -21.4% YoY
- [ ] Profitable — -$1.28B TTM
- [x] Profit growing — +86.7% YoY
- [ ] Generates cash — -$1.89B TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $25.6B market cap
- [x] Not printing shares — +1.4% shares over ~5y
- [ ] Proven track record — 1/7 profitable years
- [x] Financially stable — Altman Z 40.5 — safe

## Experience (career milestones)

- **2023** — Roche completed the acquisition of Telavant from Roivant for a purchase price of $7.1 billion…
- **FY2023** — Turned profitable: $2.60B net income after a loss year
- **FY2023** — Best year on record: $2.60B net income
- **2022** — Roivant and Pfizer unveiled Priovant Therapeutics
- **2021** — Priovant was established in September 2021 through a transaction between Roivant and Pfizer, in which Pfizer…
- **2021** — Roivant merged with special-purpose acquisition company Montes Archimedes Acquisition Corp
- **2021** — Roivant acquired Silicon Therapeutics, a small-molecule drug designer and computational physics…
- **2020** — Roivant dosed the first patient in a clinical study evaluating gimsilumab in COVID-19 patients for…
- **2019** — At the end of 2019, Roivant formed a $3 billion partnership with Sumitomo Dainippon Pharma and transferred its…

## Strengths

- High gross margin (81.2%)
- Net cash position after subtracting debt from cash
- Altman Z-Score 40.50 — low bankruptcy-risk zone

## Watch-outs

- Revenue shrinking 21.4% year over year
- Not profitable — 7594.2% net margin
- Negative free cash flow (-$1.9B)
- Thin interest coverage (-72.8×)
- Loss-making in 5 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2023 | $237M | $2.60B | -$2.21B |
| FY2024 | $118M | -$177M | -$2.17B |
| FY2025 | $19.9M | -$1.46B | -$1.96B |
| FY2026 | $19.2M | -$1.43B | -$2.02B |
| FY2027 | $1.44M | -$190M | -$271M |

---

Source: https://stockcv.com/ROIV — derived from company filings; may be delayed or incomplete. Information, not investment advice.